Quadramet 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3 
amended 
on 
IG/0557 
C.I.8.a - Introduction of or changes to a summary of 
21/05/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IAIN/0019 
C.I.z - Changes (Safety/Efficacy) of Human and 
04/05/2015 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). 
Opinions are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). 
The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union 
 
  
 
 
 
 
 
 
 
 
 
                                                
II/0018 
To widen the specification limits for samarium 
24/05/2012 
14/06/2012 
SmPC and PL 
content 
B.I.b.1.g - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Widening of the 
approved specs for starting mat./intermediates, 
which may have a significant effect on the quality of 
the AS and/or the FP 
IG/0015 
C.I.9.e - Changes to an existing pharmacovigilance 
06/08/2010 
n/a 
Annex II 
system as described in the DDPS - Changes in the 
major contractual arrangements with other persons 
or organisations involved in the fulfilment of 
pharmacovigilance obligations and described in the 
DD 
II/0016 
Update to SmPC section 4.8 and PL following a signal 
26/06/2008 
23/07/2008 
SmPC and PL 
Following the assessment of a signal detection, the CHMP 
detection assessment. 
requested that the product information for Quadramet 
should be amended to include post-marketing reports of 
Update of Summary of Product Characteristics and 
thrombocytopenia in section 4.8. The PL has been amended 
Package Leaflet 
accordingly. 
These changes were requested further to a review 
performed following the detection of a signal where post-
marketing cases of thrombocytopenia including isolated 
reports of intracranial haemorrhage, and cases in which the 
outcome was fatal have been reported. 
N/0015 
Minor change in labelling or package leaflet not 
11/04/2008 
n/a 
PL 
connected with the SPC (Art. 61.3 Notification) 
R/0014 
Renewal of the marketing authorisation. 
18/10/2007 
12/12/2007 
SmPC, 
Based upon data that have become available since the 
Quadramet  
EMA/373626/2015 
Page 2/4 
  
  
 
 
 
 
 
 
 
 
 
 
Labelling and 
granting of the marketing authorisation, the CHMP 
PL 
considers that the benefit-risk balance of Quadramet 
remains positive ad thus recommends the renewal of the 
Marketing Authorisation with unlimited validity. 
N/0013 
Minor change in labelling or package leaflet not 
13/04/2007 
n/a 
connected with the SPC (Art. 61.3 Notification) 
N/0012 
Minor change in labelling or package leaflet not 
22/09/2006 
n/a 
connected with the SPC (Art. 61.3 Notification) 
IA/0011 
IA_11_a_Change in batch size of active substance or 
23/06/2004 
n/a 
intermediate - up to 10-fold 
PL 
PL 
N/0010 
Minor change in labelling or package leaflet not 
25/05/2004 
n/a 
PL 
connected with the SPC (Art. 61.3 Notification) 
R/0009 
Renewal of the marketing authorisation. 
18/12/2002 
17/03/2003 
SmPC, Annex 
II, Labelling 
and PL 
N/0008 
Minor change in labelling or package leaflet not 
07/06/2002 
27/06/2002 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0007 
Minor change in labelling or package leaflet not 
15/03/2002 
19/04/2002 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0006 
Minor change in labelling or package leaflet not 
23/10/2001 
17/12/2001 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0005 
Minor change in labelling or package leaflet not 
23/10/2001 
n/a 
PL 
connected with the SPC (Art. 61.3 Notification) 
Quadramet  
EMA/373626/2015 
Page 3/4 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/0004 
Minor change in labelling or package leaflet not 
16/08/2000 
09/10/2000 
PL 
connected with the SPC (Art. 61.3 Notification) 
I/0003 
15_Minor changes in manufacture of the medicinal 
23/12/1998 
n/a 
product 
I/0002 
15_Minor changes in manufacture of the medicinal 
23/12/1998 
n/a 
product 
I/0001 
12_Minor change of manufacturing process of the 
23/12/1998 
n/a 
active substance 
Quadramet  
EMA/373626/2015 
Page 4/4 
  
  
 
 
 
 
 
 
 
 
 
 
 
  
